Company / Total Assets
Travere Therapeutics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$605.2M
FY2025
5-year range
$594.1M / $788.9M
FY2021-FY2025
Trend
+1.9%
vs FY2024
Sector context
#123 of 214
Health Care
What the data says
At $605M, Travere Therapeutics, Inc.'s total assets ranks #123 of 214 in the Health Care sector. Total Assets has fluctuated over the past 10 years, ranging from $520M in FY2017 to $789M in FY2023.
Based on SEC 10-K filings.
$605M in FY2025 with a 5-year CAGR of -0.1%.
Declined from $789M to $605M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -3.5%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Sector benchmark
#123 of 214 in Health CareTop 57% of 214This company $605.2M Sector average $7.5B
▼
-91.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, total assets increased 1.9% year-over-year.
- Ranks #123 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $605.2M | +1.9% |
| FY2024 | $594.1M | -24.7% |
| FY2023 | $788.9M | +17.3% |
| FY2022 | $672.6M | -13.4% |
| FY2021 | $776.6M | +27.9% |
| FY2020 | $607.4M | +0.4% |
| FY2019 | $604.8M | -14.7% |
| FY2018 | $709.2M | +36.3% |
| FY2017 | $520.3M | -0.9% |
| FY2016 | $525.3M | +2.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026